Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.
AUTOR(ES)
De Silva, M
RESUMO
The ability of azathioprine to reduce the maintenance prednisolone requirement of 31 patients with polymyalgia rheumatica (PMR) or giant cell arteritis (GCA), or both, was tested in a double-blind placebo controlled study over one year. Clinical and laboratory assessments were made at four-weekly intervals over a period of 52 weeks. A statistically significant difference (p less than 0.05) in mean prednisolone dose was noted between the two groups at the end of 52 weeks, there being a fall in steroid requirement in the azathioprine treated group.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1001834Documentos Relacionados
- Hepatocellular disease in the giant-cell arteritis/polymyalgia rheumatica syndrome.
- Long-term azathioprine in rheumatoid arthritis: a double-blind study.
- Antibodies to intermediate filaments in polymyalgia rheumatica and giant cell arteritis: a sequential study.
- Polymyalgia rheumatica: a biopsy and follow-up study.
- Polymyalgia Rheumatica and Giant Cell Arteritis
